Dr. Reddy's management to meet Bank of America on June 5

0 min read Updated on 02 Jun 2026, 04:38 AM

Reviewed by

Naman SScanX News Team

AI Summary

Dr. Reddy's Laboratories Limited announced a regulatory filing on June 1, 2026, regarding a scheduled investor meeting. The management will participate in an in-person group meet organized by Bank of America on June 5, 2026, in Hyderabad between 08:00 and 09:00 IST. The schedule is subject to change due to exigencies.

*this image is generated using AI for illustrative purposes only.

Dr. Reddy's Laboratories Limited has announced that its management will engage with a single institution and investor groups through a scheduled meeting. The company disclosed this information in a regulatory filing submitted to the exchanges on June 1, 2026.

The interaction is set to take place as an in-person group meet organized by Bank of America. The meeting is scheduled for June 5, 2026, and will be held in Hyderabad. The session is planned to take place between 08:00 and 09:00 IST.

The company noted that the schedule for the aforementioned meeting is subject to change due to any exigencies on the part of the investors or the company. The filing was signed by K Randhir Singh, Company Secretary, Compliance Officer & Head-CSR.

Date	Organized by	Location	Meeting mode	Nature of meet	Timing
05.06.2026	Bank of America	Hyderabad	In-Person	Group Meet	08:00 - 09:00 IST

Historical Stock Returns for Dr Reddys Laboratories

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.33%	-3.90%	-4.19%	-1.03%	+1.54%	+19.97%

What specific strategic initiatives or growth areas is Dr. Reddy's management likely to highlight during this meeting?

How might investor sentiment shift following the engagement, and could it influence the company's stock price?

Will the meeting provide insights into Dr. Reddy's pipeline developments or upcoming product launches?

Read Next Article

Dr. Reddy's Laboratories files Form 20-F annual report for FY26

0 min read Updated on 31 May 2026, 02:27 AM

Reviewed by

Anirudha BScanX News Team

Add as a preferred
source on Google

AI Summary

Dr. Reddy's Laboratories filed its Annual Report in Form 20-F for the fiscal year ended March 31, 2026, with the United States Securities and Exchange Commission on May 30, 2026. The filing includes annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS). The submission was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

*this image is generated using AI for illustrative purposes only.

Dr. Reddy's Laboratories filed its Annual Report in Form 20-F for the fiscal year ended March 31, 2026, with the United States Securities and Exchange Commission on May 30, 2026. The filing includes annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS), as issued by the International Accounting Standards Board (IASB).

The submission was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company disclosed that the report is accessible on its official website for stakeholders.

Filing Details

Detail	Information
Report Type	Form 20-F
Fiscal Year Ended	March 31, 2026
Filing Date	May 30, 2026
Regulatory Standard	IFRS
Filing Authority	United States Securities and Exchange Commission

The intimation was addressed to the National Stock Exchange of India Ltd., BSE Limited, New York Stock Exchange Inc., and NSE IFSC Ltd. K Randhir Singh, Company Secretary, Compliance Officer & Head-CSR, signed the disclosure on behalf of Dr. Reddy's Laboratories Limited.

Historical Stock Returns for Dr Reddys Laboratories